| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
|
J Clin Oncol
|
1999
|
9.22
|
|
2
|
OATP1B1 polymorphism as a determinant of erythromycin disposition.
|
Clin Pharmacol Ther
|
2012
|
2.43
|
|
3
|
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.
|
Proc Natl Acad Sci U S A
|
2000
|
2.23
|
|
4
|
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
|
J Clin Oncol
|
2000
|
2.22
|
|
5
|
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
|
Clin Cancer Res
|
1999
|
2.02
|
|
6
|
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
|
Clin Cancer Res
|
1996
|
1.82
|
|
7
|
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
|
J Clin Oncol
|
1998
|
1.80
|
|
8
|
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.
|
Biochem Pharmacol
|
1998
|
1.46
|
|
9
|
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.
|
Mayo Clin Proc
|
1999
|
1.46
|
|
10
|
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
|
J Clin Oncol
|
2001
|
1.41
|
|
11
|
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
|
Cancer Res
|
1994
|
1.39
|
|
12
|
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
|
Clin Cancer Res
|
2001
|
1.34
|
|
13
|
Phase I study of phenylacetate administered twice daily to patients with cancer.
|
Cancer
|
1995
|
1.33
|
|
14
|
Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.
|
Cancer Res
|
2000
|
1.32
|
|
15
|
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
|
Cancer Res
|
1998
|
1.28
|
|
16
|
The control of prostate-specific antigen expression and gene regulation by pharmacological agents.
|
Pharmacol Rev
|
2001
|
1.28
|
|
17
|
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
|
Clin Pharmacol Ther
|
2007
|
1.28
|
|
18
|
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?
|
J Pharmacol Exp Ther
|
2001
|
1.24
|
|
19
|
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
|
Expert Opin Investig Drugs
|
2000
|
1.23
|
|
20
|
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
|
Pharmacogenomics J
|
2009
|
1.18
|
|
21
|
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
|
Blood
|
1996
|
1.15
|
|
22
|
Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women.
|
Am J Cardiol
|
1995
|
1.14
|
|
23
|
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
|
Clin Cancer Res
|
2000
|
1.13
|
|
24
|
Methods for extracting and amplifying genomic DNA isolated from frozen serum.
|
Nat Biotechnol
|
1998
|
1.11
|
|
25
|
A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
|
Cancer
|
1998
|
1.09
|
|
26
|
Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer.
|
Urology
|
1998
|
1.08
|
|
27
|
Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
|
Antimicrob Agents Chemother
|
1997
|
1.07
|
|
28
|
The androgen receptor gene and its influence on the development and progression of prostate cancer.
|
J Pathol
|
2001
|
1.07
|
|
29
|
Activity of thalidomide in AIDS-related Kaposi's sarcoma.
|
J Clin Oncol
|
2000
|
1.06
|
|
30
|
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.
|
Biochem Biophys Res Commun
|
2000
|
1.06
|
|
31
|
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
|
Leukemia
|
2005
|
1.04
|
|
32
|
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
|
Leukemia
|
2001
|
1.03
|
|
33
|
Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells.
|
Mol Pharmacol
|
1995
|
1.02
|
|
34
|
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
|
J Clin Oncol
|
2001
|
1.00
|
|
35
|
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
|
Microvasc Res
|
2000
|
0.99
|
|
36
|
Effect of ABCC2 (MRP2) transport function on erythromycin metabolism.
|
Clin Pharmacol Ther
|
2011
|
0.99
|
|
37
|
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.
|
Tumori
|
1998
|
0.99
|
|
38
|
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
|
Clin Cancer Res
|
1999
|
0.98
|
|
39
|
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
|
Clin Cancer Res
|
2001
|
0.98
|
|
40
|
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
|
J Natl Cancer Inst
|
1994
|
0.98
|
|
41
|
A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
|
Cancer
|
2001
|
0.98
|
|
42
|
Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
|
Surgery
|
2001
|
0.97
|
|
43
|
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
|
Blood
|
1995
|
0.96
|
|
44
|
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
|
Cancer
|
1995
|
0.95
|
|
45
|
The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.
|
J Surg Res
|
2000
|
0.95
|
|
46
|
Malignant ascites as only manifestation of metastatic prostate cancer.
|
Prostate Cancer Prostatic Dis
|
1999
|
0.95
|
|
47
|
The CYP2C19*17 variant is not independently associated with clopidogrel response.
|
J Thromb Haemost
|
2013
|
0.94
|
|
48
|
Thalidomide neuropathy in patients treated for metastatic prostate cancer.
|
Muscle Nerve
|
2001
|
0.94
|
|
49
|
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.
|
Cancer Chemother Pharmacol
|
1998
|
0.93
|
|
50
|
Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo.
|
Int J Oncol
|
1999
|
0.93
|
|
51
|
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
|
J Clin Oncol
|
1998
|
0.92
|
|
52
|
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
|
J Clin Oncol
|
2001
|
0.91
|
|
53
|
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
|
Cancer Chemother Pharmacol
|
1996
|
0.91
|
|
54
|
Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
|
Pharmacotherapy
|
1996
|
0.90
|
|
55
|
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
|
J Clin Pharmacol
|
1999
|
0.89
|
|
56
|
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.
|
J Nucl Med
|
2001
|
0.88
|
|
57
|
A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
|
Clin Cancer Res
|
1999
|
0.88
|
|
58
|
Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer.
|
J Clin Oncol
|
2001
|
0.88
|
|
59
|
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
|
J Clin Oncol
|
1997
|
0.87
|
|
60
|
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
|
Cancer Res
|
1996
|
0.86
|
|
61
|
Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.
|
Clin Pharmacokinet
|
1997
|
0.86
|
|
62
|
Laparoscopic continuous hyperthermic peritoneal perfusion.
|
J Am Coll Surg
|
2001
|
0.86
|
|
63
|
Drug-induced lupus associated with COL-3: report of 3 cases.
|
Arch Dermatol
|
2001
|
0.85
|
|
64
|
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
|
Br J Cancer
|
2008
|
0.85
|
|
65
|
Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target.
|
Ann Pharmacother
|
1997
|
0.85
|
|
66
|
Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine.
|
Am J Med
|
1988
|
0.84
|
|
67
|
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
|
Clin Cancer Res
|
2001
|
0.84
|
|
68
|
Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
|
J Urol
|
2000
|
0.84
|
|
69
|
Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.
|
Cancer Chemother Pharmacol
|
1999
|
0.84
|
|
70
|
Approaches to preclinical screening of antiangiogenic agents.
|
Semin Oncol
|
2001
|
0.84
|
|
71
|
Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.
|
Clin Cancer Res
|
1998
|
0.83
|
|
72
|
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
|
Clin Cancer Res
|
2001
|
0.83
|
|
73
|
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.
|
Int J Oncol
|
2001
|
0.82
|
|
74
|
Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.
|
Antimicrob Agents Chemother
|
1997
|
0.82
|
|
75
|
Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.
|
J Clin Pharmacol
|
1995
|
0.82
|
|
76
|
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
|
J Clin Oncol
|
1995
|
0.82
|
|
77
|
A preliminary risk-benefit assessment of paclitaxel.
|
Drug Saf
|
1995
|
0.81
|
|
78
|
Mifepristone: antineoplastic studies.
|
Clin Obstet Gynecol
|
1996
|
0.81
|
|
79
|
Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer.
|
J Investig Med
|
1998
|
0.81
|
|
80
|
The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells.
|
Prostate
|
1996
|
0.81
|
|
81
|
Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
|
Cancer J Sci Am
|
1997
|
0.81
|
|
82
|
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
|
Ann Intern Med
|
1997
|
0.80
|
|
83
|
A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.
|
Biomed Chromatogr
|
2000
|
0.80
|
|
84
|
Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
|
Blood
|
1994
|
0.80
|
|
85
|
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
|
Clin Cancer Res
|
1998
|
0.80
|
|
86
|
Diltiazem-cyclosporine interaction in cardiac transplant recipients: impact on cyclosporine dose and medication costs.
|
Am J Med
|
1991
|
0.80
|
|
87
|
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
|
Clin Cancer Res
|
2000
|
0.79
|
|
88
|
Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
|
World J Urol
|
1996
|
0.79
|
|
89
|
In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.
|
Cancer Lett
|
1997
|
0.79
|
|
90
|
New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12.
|
Angiogenesis
|
1997
|
0.79
|
|
91
|
A phase I study of pentosan polysulfate sodium in patients with advanced malignancies.
|
Ann Oncol
|
1996
|
0.79
|
|
92
|
The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
|
Pharmacotherapy
|
1996
|
0.79
|
|
93
|
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
|
J Clin Oncol
|
1997
|
0.79
|
|
94
|
Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma.
|
Hum Gene Ther
|
1999
|
0.79
|
|
95
|
Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.
|
J Pharmacol Exp Ther
|
2000
|
0.78
|
|
96
|
The androgen receptor: genetic considerations in the development and treatment of prostate cancer.
|
J Mol Med (Berl)
|
1999
|
0.78
|
|
97
|
Contribution of the OATP1B subfamily to cancer biology and treatment.
|
Clin Pharmacol Ther
|
2012
|
0.78
|
|
98
|
Phenylacetate pharmacokinetics based on iterative two-stage population analysis.
|
Pharmacotherapy
|
2001
|
0.78
|
|
99
|
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.
|
Invasion Metastasis
|
2000
|
0.78
|
|
100
|
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.
|
J Natl Med Assoc
|
1997
|
0.78
|
|
101
|
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry.
|
J Chromatogr B Biomed Sci Appl
|
2001
|
0.78
|
|
102
|
Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.
|
Pharmacotherapy
|
1999
|
0.77
|
|
103
|
Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
|
Am J Hematol
|
1996
|
0.77
|
|
104
|
Thalidomide, an antiangiogenic agent with clinical activity in cancer.
|
Biomed Pharmacother
|
2002
|
0.76
|
|
105
|
SLCO transport genes in prostate cancer--letter.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.76
|
|
106
|
Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor.
|
Br J Cancer
|
1999
|
0.76
|
|
107
|
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.
|
Am J Hematol
|
2001
|
0.76
|
|
108
|
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
|
Urol Int
|
1999
|
0.75
|
|
109
|
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.
|
Biotechniques
|
2002
|
0.75
|
|
110
|
Ondansetron versus dexamethasone.
|
Lancet
|
1991
|
0.75
|
|
111
|
Mutated androgen receptors of prostate-cancer cells.
|
N Engl J Med
|
1995
|
0.75
|
|
112
|
Diarrhea precipitated by oral liquid medication.
|
Am J Med
|
1990
|
0.75
|
|
113
|
Taxanes in hormone-refractory prostate cancer.
|
Cancer Pract
|
2000
|
0.75
|
|
114
|
Adaptive control with feedback of suramin using intermittent infusions.
|
J Clin Oncol
|
1994
|
0.75
|
|
115
|
High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma.
|
J Pharm Biomed Anal
|
2000
|
0.75
|
|
116
|
Comparative study of the clinical efficacy of two dosing regimens of flutamide.
|
Mol Urol
|
2000
|
0.75
|
|
117
|
Suramin-induced neutropenia.
|
Eur J Cancer
|
1996
|
0.75
|
|
118
|
Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.
|
Cancer Treat Rev
|
1996
|
0.75
|
|
119
|
Peripheral neuropathy in HIV patient after isoniazid therapy initiated.
|
DICP
|
1991
|
0.75
|
|
120
|
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
|
J Pharmacokinet Biopharm
|
1998
|
0.75
|
|
121
|
Suramin administration is associated with a decrease in serum calcium levels.
|
World J Urol
|
2000
|
0.75
|
|
122
|
Nitrate tolerance: does tid isosorbide dinitrate mean dosing every eight hours?
|
DICP
|
1991
|
0.75
|
|
123
|
A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
|
Oncol Rep
|
1998
|
0.75
|
|
124
|
Anaphylactoid reaction with suramin.
|
Pharmacotherapy
|
1994
|
0.75
|
|
125
|
Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
|
J Clin Pharmacol
|
1997
|
0.75
|
|
126
|
Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay.
|
Clin Cancer Res
|
2001
|
0.75
|
|
127
|
Aseptic meningitis associated with muromonab-CD3.
|
DICP
|
1991
|
0.75
|
|
128
|
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
|
Neoplasma
|
1999
|
0.75
|
|
129
|
Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
|
Pharmacotherapy
|
1997
|
0.75
|
|
130
|
Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents.
|
Ther Drug Monit
|
1996
|
0.75
|